- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03320395
Treatment of Ex-vivo Small Bowel Mucosa With a Dedicated Radiofrequency Ablation (SB-RFA) Catheter.
Gastrointestinal angiodysplasia (GIAD, a.k.a. angioectasia, arteriovenous malformations or AVM, and vascular ectasia) are mucosal or submucosal dilated blood vessels, usually multifocal, and a frequent cause of obscure GI bleeding, especially mid-small bowel hemorrhage.
Endoscopic treatment using argon plasma coagulation (APC) is popular but presents limitations as application of the therapy is not uniform, and passing the catheter repetitively through the enteroscope may not be possible. Despite endoscopic treatment rebleeding rates are high, between 25 to 50%.
An improvement in our ability to treat GIAD endoscopically is desirable. An ablation catheter would need to be easy to use repetitively through the enteroscope, be more maneuverable to direct treatment to the lesions, and also cover more area of intestinal mucosa per treatment compared to APC, and it should be low risk for damage to the healthy intestinal mucosa.
Radiofrequency ablation (RFA) may hold the answer. It's efficacy for treatment of superficial Barrett esophagus is undisputed, and it has recently been used with success to treat gastric antral vascular ectasia (GAVE) a condition which is remarkably similar to GIAD.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Gastrointestinal angiodysplasia (GIAD, a.k.a. angioectasia, arteriovenous malformations or AVM, and vascular ectasia) are mucosal or submucosal dilated blood vessels lined by epithelium with no overlying mucosal lesion formed due to a combination of sub-mucosal vein obstruction, hypoxemia and neovascularization. It is a frequent cause of obscure GI bleeding, and the most common finding when evaluating mid-small bowel hemorrhage. It is also more common in patients with underlying valvular heart disease (especially aortic stenosis), end-stage renal disease, and von Willebrand disease (acquired or congenital). These lesions are usually multifocal as forty to 60% of the patients will have more than one About half stop bleeding spontaneously but at least a quarter of patients will suffer recurrent GI bleeding manifested by overt bleeding (melena or hematochezia), persistent fecal occult blood or persistent iron deficiency anemia.
Management includes endoscopic therapy, surgery, therapeutic angiography, and pharmacological treatment. Endoscopic therapy including thermal methods (multi-polar electrocoagulation, argon plasma coagulation, laser), injections (sclerosants, saline, epinephrine), and mechanical methods (hemostatic clips, band ligators) are widely used to treat all causes of GI bleeding including GIAD. Argon plasma coagulation (APC) is the preferred mode of endoscopic therapy for GIAD due to availability, relative ease of use, and a perceived superficial rather than deep depth of burn; however, studies have shown that depth of tissue injury can be substantial. APC therapy may not be uniform as adequacy and depth of ablation depends on the presence of debris, mucous or blood between the APC probe and tissue, and the ability to target the tissue in the presence of breathing, intestinal peristalsis, and scope position. The APC catheter can also bend during repeated insertions, a necessary maneuver to remove the burned tissue debris on the tip of the catheter which otherwise affects the argon plasma beam and this may terminally damage it.
Angioectasia rebleeding rates are high, at least 25 to over 50%. An improvement in our ability to treat small bowel GIAD is desirable. An ablation catheter would need to be easy to use repetitively through the enteroscope, be more maneuverable to direct treatment to the lesions, and also cover more area of intestinal mucosa per treatment compared to APC, and it should be low risk for damage to the healthy intestinal mucosa while treating GIAD.
Radiofrequency ablation (RFA) may hold the answer. It's efficacy for treatment of superficial Barrett esophagus is undisputed, and it has recently been used with success to treat gastric antral vascular ectasia (GAVE) a condition which is remarkably similar to GIAD.
This study will determine the depth of burn achieved on fresh and healthy small bowel explants using a dedicated small bowel RFA catheter at usual RFA settings.
Study Type
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Understand and provide informed consent.
- All patients must be over 18 years of age, otherwise no age restrictions.
- Healthy small bowel tissue has cleared by pathology as tissue that would otherwise be discarded.
- Patients who are undergoing planned resection of the small bowel will be recruited until the study endpoints are met.
Exclusion Criteria:
- Inability to provide informed consent.
- Inability to isolate disease free section of small bowel or sufficient small bowel to perform SB-RFA treatment..
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Small bowel RFA treatment
Five small bowel samples each of the duodenum, jejunum and ileum will be recruited treated.
|
The samples will be spread and fixed using needles. The prototype RFA-SB ablation catheter will be applied by the PI as follows to each section of duodenum, jejunum and ileum. The treating paddle of the prototype RFA-SB catheter will be pushed on the small bowel mucosa exerting the same pressure that would be applied endoscopically. 12 J/cm2 will be applied every time with a 20 second interval between applications to simulate clinical practice. There will be two single applications to two separate specimen sites. There will be two double applications to two separate specimen sites. There will be two triple applications to two separate specimen sites. There will be two quadruple applications to two separate specimen sites. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Depth of small bowel mucosa treatment
Time Frame: 3 months
|
Study of the effect of RFA treatment on ex-vivo healthy small bowel mucosa including duodenum, jejunum, and ileum.
|
3 months
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FLA 16-032
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Angiodysplasia
-
Unity Health TorontoActive, not recruitingGastrointestinal Diseases | Obscure Gastrointestinal Bleeding | Gastrointestinal Bleed | Angiodysplasia IntestineCanada
-
Robert BenamouzigCompleted
-
Assiut UniversityNot yet recruitingAngiodysplasia | Hematological Disease
-
University of AlbertaCompletedGastric Antral Vascular EctasiaCanada
-
Mayo ClinicNot yet recruitingCirrhosis | Gastric Antral Vascular EctasiaUnited States
-
The University of Texas Health Science Center,...RecruitingGastric Antral Vascular EctasiaUnited States
-
Hôpital Edouard HerriotCapso Vision, Inc.CompletedAnemia | Polyps | Angiodysplasia | Gastrointestinal Bleedings | Méléna
-
Radboud University Medical CenterUniversity Medical Center Groningen; Catharina Ziekenhuis Eindhoven; St. Antonius... and other collaboratorsCompletedAnemia | Vascular Malformations | Gastrointestinal Hemorrhage | AngiodysplasiaNetherlands
-
Assiut UniversityNot yet recruitingGAVE - Gastric Antral Vascular Ectasia
Clinical Trials on Small bowel RFA treatment
-
University Hospital, GenevaCentre Hospitalier Universitaire VaudoisUnknownIntestinal ObstructionSwitzerland
-
Nantes University HospitalRecruiting
-
University Hospital FreiburgRecruitingGastroIntestinal BleedingGermany
-
Asian Institute of Gastroenterology, IndiaCompletedSmall Bowel Disease | Small Bowel Ulcers | Capsule Endoscopy | Small Bowel Tumor
-
Vanderbilt University Medical CenterActive, not recruitingObesity | Malnutrition | Weight Loss | Micronutrient DeficiencyUnited States
-
WellSpan HealthChristiana Care Health Services; University of California, IrvineCompletedSmall Bowel ObstructionUnited States
-
Olympus Surgical Technologies EuropeCompletedApnea, SleepUnited States
-
Odense University HospitalCompletedSimulation | Endoscopy | Education | Small Bowel Disease | Small Bowel Capsule EndoscopyDenmark
-
University of Southern CaliforniaCompletedObscure Gastrointestinal Bleeding (Occult or Overt)United States
-
Mayo ClinicMedtronic - MITGCompletedCrohn's DiseaseUnited States